Fortis Q1 Profit Jumps 57%; Expansion Drives Growth

 

Gurugram, August 7 – http://Fortis HealthcareFortis Healthcare has reported a 57% year-on-year increase in its net profit for the first quarter of FY2025. The hospital chain posted ₹260 crore in net profit, compared to ₹166 crore in the same period last year. This sharp rise is being attributed to robust hospital performance, diagnostics expansion, and tighter cost controls.

 

According to the financials released, Fortis clocked in revenue of ₹1,856 crore for the April–June quarter, registering an 8.6% year-on-year growth. The hospital business contributed ₹1,456 crore to the total revenue—marking a significant 12.8% rise.

 

The diagnostics segment, however, saw a dip. Revenues from this vertical fell 6.4% to ₹399 crore, primarily due to lower COVID-related testing compared to last year. Despite this, the company’s overall profitability remained strong.

 

EBITDA Shows Strong Momentum

 

The company’s EBITDA (Earnings Before Interest, Tax, Depreciation and Amortisation) rose by 10.4% to ₹365 crore in Q1. The EBITDA margin remained stable at 19.7%, indicating efficient operational performance and cost discipline.

 

Fortis attributed this growth to a mix of high-end procedures, strong occupancy rates in its flagship hospitals, and better case mix. International patient inflow has also returned to pre-COVID levels, contributing to better margins.

 

Chairman’s Note

 

Fortis Healthcare Chairman Ravi Rajagopal stated,

 

> “We are witnessing a strong momentum in our hospital vertical. Our expansion strategy is on track, and we continue to invest in technology and infrastructure upgrades to deliver world-class care.”

 

The company is actively pursuing brownfield expansions across several metro and Tier-II cities. Plans include bed additions and new centres under the diagnostics vertical.

 

Future Outlook

 

Analysts see Fortis’ Q1 results as a strong indicator of sustained recovery and profitability. With international travel normalizing and medical tourism resuming, the outlook remains bullish.

 

The company is also optimistic about increased demand for elective surgeries and specialized treatments. Fortis plans to scale its high-end offerings such as oncology, transplants, and robotic surgeries.

Related Posts

Galgotia Outrage in AI Expo evokes SOS from Domestic MedTech Industry

Chinese ‘Made in India’ Fakes brazening out with Impunity in Here too New Delhi: Chinese slur on AI Expo, thanks to Galgotia fiasco, has hit a raw nerve in domestic…

Innovation & Biomedical Skill Centre (IBSC) is transforming Biomedical & Medical Device Workforce Scenario

Landmark Industry-Academia Meet in AMTZ Visakhapatnam: Andhra Pradesh MedTech Zone (AMTZ), India’s leading MedTech ecosystem, hosted a landmark Industry–Academia Meet to commemorate eight transformative years of the Innovation and Biomedical…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

TN, Karnataka, Rajasthan declare highest number of NSQs in January

TN, Karnataka, Rajasthan declare highest number of NSQs in January

Centre reorganises CDSCO Zone Baddi amid Drug Quality Concerns

Centre reorganises CDSCO Zone Baddi amid Drug Quality Concerns

CDSCO modifies norms for testing permissions to speed up drug approvals

CDSCO modifies norms for testing permissions to speed up drug approvals

British men jailed for smuggling cocaine into Bali

British men jailed for smuggling cocaine into Bali

Andhra milk adulteration: Four dead, seven in critical condition

Andhra milk adulteration: Four dead, seven in critical condition

Allahabad HC rejects bail pleas of two accused in Phensedyl syrup case

Allahabad HC rejects bail pleas of two accused in Phensedyl syrup case